Increased survival with enzalutamide in prostate cancer after chemotherapy Academic Article uri icon

Overview

MeSH Major

  • Androgen Receptor Antagonists
  • Antineoplastic Agents
  • Phenylthiohydantoin

abstract

  • Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIRM ClinicalTrials.gov number, NCT00974311.).

publication date

  • September 27, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1207506

PubMed ID

  • 22894553

Additional Document Info

start page

  • 1187

end page

  • 97

volume

  • 367

number

  • 13